Earnings History Data for AC Immune SA (ACIU) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

AC Immune SA

AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
04-08-2023	PM		ACIU	AC Immune SA	244.17	-0.22	-0.22	-0.24	AC Immune GAAP EPS of -$0.20 beats by $0.02 [8/4/2023 7:59 AM]	3.00	0.11 (3.81%)	3.05	0.16 (5.54%)	1.68 - 3.83	59,339	90,000	12,742
AC Immune GAAP EPS of -$0.20 beats by $0.02 [8/4/2023 7:59 AM]
28-04-2023	PM	8:00 AM ET (Apr 28)	ACIU	AC Immune SA	160.55	-0.23	-0.24	-0.25	AC Immune GAAP EPS of -CHF0.21 [4/28/2023 7:31 AM]	1.93	0.05 (2.66%)	1.87	-0.01 (-0.53%)	1.68 - 3.90	178,142	50,000	8,903
AC Immune GAAP EPS of -CHF0.21 [4/28/2023 7:31 AM]
16-03-2023	PM	8:00 AM ET (Mar 16)	ACIU	AC Immune SA	194.35	-0.24	-0.28	-0.28	AC Immune Non-GAAP EPS of -CHF 0.81, revenue of CHF 3.9M [3/16/2023 7:57 AM]	2.30	0.0 (0.00%)	0.0	0.0 (0.00%)	1.68 - 4.84	47,014	50,000	0
AC Immune Non-GAAP EPS of -CHF 0.81, revenue of CHF 3.9M [3/16/2023 7:57 AM]
28-10-2022	PM	7:30 AM ET (Oct 28)	ACIU	AC Immune	258.00	-0.17	-0.24	0.00	AC Immune Non-GAAP EPS of -CHF0.16, revenue of CHF3.93M [10/28/2022 9:00 AM]	2.90	-0.20 (-6.61%)	3.05	-0.05 (-1.61%)	2.06 - 8.14	90,857	50,000	2,504
AC Immune Non-GAAP EPS of -CHF0.16, revenue of CHF3.93M [10/28/2022 9:00 AM]
28-07-2022	PM		ACIU	AC Immune	274.00	-0.24	-0.24	0.00	AC Immune Non-GAAP EPS of -$0.23 in-line [7/28/2022 8:39 AM]	3.57	0.19 (5.70%)	3.38	0.0 (0.00%)	2.06 - 12.61	52,536	40,000	420
AC Immune Non-GAAP EPS of -$0.23 in-line [7/28/2022 8:39 AM] AC Immune Reports Second Quarter 2022 Financial Results and Provides Corporate Update [Jul-28-22 07:30AM]
28-04-2022	PM	7:30 AM ET (Apr 28)	ACIU	AC Immune SA	318.89	-0.25	-0.23	-0.25	AC Immune GAAP EPS of -$0.23 in-line [4/28/2022 8:15 AM]	3.36	-0.09 (-2.61%)	3.45	0.0 (0.00%)	3.34 - 12.61	115,807	60,000	268
AC Immune GAAP EPS of -$0.23 in-line [4/28/2022 8:15 AM] AC Immune to Present at the B. Riley Annual Neuro & Ophthalmology Virtual Investor Conference [Apr-27-22 07:55AM] AC Immune Reports First Quarter 2022 Financial Results and Provides Corporate Update [Apr-28-22 07:30AM]
08-11-2021	PM	7:00 AM ET (Nov 8)	ACIU	AC Immune	528.00	-0.24	-0.29	0.00	AC Immune EPS beats by $0.08, misses on revenue [11/8/2021 7:28 AM]	7.35	0.02 (0.27%)	8.05	0.72 (9.82%)	4.80 - 12.61	871,984	640,000	413,093
AC Immune EPS beats by $0.08, misses on revenue [11/8/2021 7:28 AM] AC Immune estimates families affected by Alzheimer’s to nearly triply by 2050 [11/8/2021 7:03 AM] AC Immune Reports Third Quarter 2021 Financial Results and Provides Corporate Update [Nov-08-21 07:00AM] Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline [Nov-05-21 03:00PM] AC Immune (ACIU) Reports Q3 Loss, Misses Revenue Estimates [Nov-08-21 08:25AM]
28-04-2021	PM		ACIU	Ac Immune Sa	511.00	-0.25	-0.21	0.00	AC Immune reports Q1 results; outlook [4/28/2021 7:24 AM]	6.91	-0.23 (-3.22%)	0.0	0.0 (0.00%)	4.42 - 13.00	131,170	170,000	0
AC Immune reports Q1 results; outlook [4/28/2021 7:24 AM] AC Immune Reports First Quarter 2021 Financial Results and Provides Corporate Update [Apr-28-21 07:00AM] AC Immune (ACIU) Reports Q1 Loss, Misses Revenue Estimates [Apr-28-21 08:45AM]
23-03-2021	PM	7:00 AM ET (Mar 23)	ACIU	Ac Immune Sa	572.00	-0.30	-0.29	0.00	AC Immune EPS misses by CHF0.02, misses on revenue; outlook [3/23/2021 7:35 AM]	7.67	-0.04 (-0.52%)	7.72	0.01 (0.13%)	4.42 - 13.00	238,295	340,000	1,472
AC Immune EPS misses by CHF0.02, misses on revenue; outlook [3/23/2021 7:35 AM] AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook [Mar-23-21 07:00AM] Recap: AC Immune Q4 Earnings [Mar-23-21 08:01AM]
13-11-2020	PM		ACIU	Ac Immune Sa	369.00	-0.28	-0.24	0.00	AC Immune EPS misses by CHF0.02, beats on revenue [11/13/2020 7:22 AM]	5.15	-0.03 (-0.58%)	5.18	0.0 (0.00%)	4.07 - 13.00	173,487	536,388	3,722